abrdn Life Sciences Investors (NYSE:HQL) Stock Short Interest Report for September

Key Points

• Short interest rose sharply: Shares sold short increased 67.3% to 112,812 as of September 30, representing 0.4% of outstanding shares and a 1.0-day days-to-cover ratio.
• Dividend yield remains high: abrdn Life Sciences Investors paid a quarterly dividend of $0.62 per share, equal to $2.48 annually and a 14.4% yield.
• Institutional ownership expanded: Several investment firms initiated or increased positions, while institutional investors collectively owned 32.21% of the fund.

abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totaling 112,812 shares, an increase of 67.3% from the September 15th total of 67,415 shares. Currently, 0.4% of the company's stock are short sold. Based on an average trading volume of 112,776 shares, the days-to-cover ratio is currently 1.0 days.

abrdn Life Sciences Investors Trading Up 0.6%

Shares of HQL stock opened at $17.24 on Friday. The firm has a 50-day moving average of $19.86 and a 200-day moving average of $18.82. abrdn Life Sciences Investors has a one year low of $15.66 and a one year high of $22.67.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 14.4%. The ex-dividend date of this dividend was Monday, August 24th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Independent Financial Group LLC purchased a new position in shares of abrdn Life Sciences Investors during the 1st quarter valued at about $211,000. WNY Asset Management LLC bought a new stake in abrdn Life Sciences Investors in the 1st quarter worth approximately $239,000. Citadel Advisors LLC purchased a new stake in abrdn Life Sciences Investors in the second quarter worth approximately $287,000. Wedbush Securities Inc. boosted its stake in abrdn Life Sciences Investors by 50.6% in the second quarter. Wedbush Securities Inc. now owns 15,960 shares of the company's stock worth $319,000 after buying an additional 5,360 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in abrdn Life Sciences Investors by 17.6% in the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company's stock worth $387,000 after buying an additional 3,562 shares in the last quarter. Institutional investors own 32.21% of the company's stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors NYSE: HQL is a diversified, closed-end investment company focused on the life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related industries.

Its portfolio may include both publicly traded and privately held businesses across various stages of development, from emerging companies developing new therapies and technologies to more established healthcare enterprises.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.